SCHEMBL8736703

SCHEMBL8736703

N#Cc1ccccc1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
CYP19A1 P11511 1/20 0.47
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CASP3 P42574 1/20 0.45
NOX4 Q9NPH5 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
PKM P14618 1/20 0.44
BACE1 P56817 1/20 0.43
RECQL P46063 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
THRB P10828 1/20 0.42
GALR3 O60755 1/20 0.42
RAB9A P51151 1/20 0.42
GRM5 P41594 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28744387 0.87 ALDH1A1 (0.49) ALDH1A1MAPTSMN1; SMN2CASP3KMT2A
SCHEMBL8544187 0.85 CASP3 (0.49) ALDH1A1SMN1; SMN2CASP3KMT2APKM
SCHEMBL18974296 0.83 TGM2 (0.57) ALDH1A1MAPT
SCHEMBL15584122 0.83 CASP3 (0.45) ALDH1A1MAPTSMN1; SMN2CASP3KMT2A
SCHEMBL2527719 0.82 CASP3 (0.48) ALDH1A1CASP3RAB9AGRM5
SCHEMBL1854606 0.80 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2CASP3NOX4
SCHEMBL9030149 0.78 PRKAG1 (0.53) ALDH1A1CASP3
SCHEMBL6166132 0.78 MMP2 (0.47) ALDH1A1MAPTCASP3KMT2AMEN1
SCHEMBL13627952 0.77 ALDH1A1 (0.41) ALDH1A1CYP19A1MAPTSMN1; SMN2NOX4
SCHEMBL1630498 0.76 ALDH1A1 (0.53) ALDH1A1MAPTKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017049409-A1 COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2017-03-30 WO disclosed
WO-2017049409-A1 COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2017-03-30 WO disclosed
EP-2640731-B9 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2015-11-25 EP disclosed
EP-2640731-B1 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2015-07-08 EP disclosed
US-9062060-B2 Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors H. LUNDBECK A/S (DK) 2015-06-23 US disclosed
US-9062060-B2 Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors H. LUNDBECK A/S (DK) 2015-06-23 US disclosed
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors H. LUNDBECK A/S (DK) 2014-12-04 US disclosed
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors H. LUNDBECK A/S (DK) 2014-12-04 US disclosed
US-8796304-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2014-08-05 US disclosed
US-8796304-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2014-08-05 US disclosed
US-8673890-B2 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist JANSSEN PHARMACEUTICA NV (BE) 2014-03-18 US disclosed
US-8552045-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2013-10-08 US disclosed
US-8552045-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2013-10-08 US disclosed
US-20120129836-A1 Imidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2012-05-24 US disclosed
US-20120129836-A1 Imidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2012-05-24 US disclosed
WO-2012065612-A1 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2012-05-24 WO disclosed
US-20110105490-A1 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129836-A1 Imidazole derivatives as PDE10A enzyme inhibitors PDE5A, PDE3A, PDE3B ALDH1A1 80/4885CYP19A1 289/4885MAPT 136/4885
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors PDE12, PDE5A, PDE10A ALDH1A1 113/4885CYP19A1 303/4885MAPT 160/4885
US-20110105490-A1 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST F2R, F2RL1, F2RL3 ALDH1A1 1921/4885CYP19A1 1433/4885MAPT 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.